• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Produced by Mary Caffrey

home / authors / produced-by-mary-caffrey

Articles

Giovanni Abbadessa, MD, PhD | Image: ModeX Therapeutics

What Would Make Therapy Last? How About 2 Targets Each on B Cells and T Cells?

January 10th 2026

The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology.

Daniel C. Kendzierski, PharmD, BCOP | Image: LinkedIn

Remote Clinical Pharmacists Saved Nearly $9M, Helped Practices Meet EOM Targets

August 21st 2025
Understanding What Recent Court Action Means to 340B Reform

Understanding What Recent Court Action Means to 340B Reform

May 19th 2025
Woman shocked at bill | Image credit: Fzkes for iStock

Meeting the Financial Needs of Patients With Chronic Conditions

April 12th 2025
Exact Sciences lab worker | Image: Exact Sciences

Flatiron’s Afghahi Addresses Testing Reimbursement Landscape, Opportunities in Exact Sciences Partnership

April 10th 2025
Noelle LoConte, MD | Image credit: University of Wisconsin

What Recent Evidence Is Telling Us About Alcohol and Cancer

February 19th 2025

Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.

Surgeon General logo

“This Is Important Information to Get Out”

February 19th 2025
Rikki Cannioto, PhD, EdD, MS | Image: Roswell Park CCC

Rikki Cannioto, PhD, EdD, MS: “There Is a Gap in Public Health Awareness”

February 19th 2025
Dr Bruno Sangro Discusses Results for EMERALD-1 in Unresectable Hepatocellular Carcinoma

Dr Bruno Sangro Discusses Results for EMERALD-1 in Unresectable Hepatocellular Carcinoma

January 19th 2024

The study’s senior author discusses how the combined mechanisms of action produced benefit in progression-free survival.

EBO logo

Understanding AGAVE-201 and Unmet Need in Chronic GVHD

January 6th 2024
© 2026 MJH Life Sciences
AJMC®
All rights reserved.